The estimated Net Worth of Eben Tessari is at least 3.54 百万$ dollars as of 1 September 2024. Eben Tessari owns over 6,463 units of Kiniksa Pharmaceuticals International Plc stock worth over 3,043,766$ and over the last 3 years Eben sold KNSA stock worth over 497,119$.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Eben Tessari KNSA stock SEC Form 4 insiders trading
Eben has made over 11 trades of the Kiniksa Pharmaceuticals International Plc stock since 2021, according to the Form 4 filled with the SEC. Most recently Eben exercised 6,463 units of KNSA stock worth 157,309$ on 1 September 2024.
The largest trade Eben's ever made was selling 17,500 units of Kiniksa Pharmaceuticals International Plc stock on 27 August 2024 worth over 470,925$. On average, Eben trades about 3,611 units every 82 days since 2021. As of 1 September 2024 Eben still owns at least 125,052 units of Kiniksa Pharmaceuticals International Plc stock.
You can see the complete history of Eben Tessari stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Eben Tessari's mailing address?
Eben's mailing address filed with the SEC is , 23 OLD BOND STREET, THIRD FLOOR, LONDON, X0, W1S 4PZ.
Insiders trading at Kiniksa Pharmaceuticals International Plc
Over the last 7 years, insiders at Kiniksa Pharmaceuticals International Plc have traded over 11,259,873$ worth of Kiniksa Pharmaceuticals International Plc stock and bought 3,912,796 units worth 71,248,379$ . The most active insiders traders include Bros. Advisors Lp667, L.P.B...、James E Deerfield Mgmt L.P....、Bros. Advisors Lp667, L.P.B.... On average, Kiniksa Pharmaceuticals International Plc executives and independent directors trade stock every 22 days with the average trade being worth of 1,208,067$. The most recent stock trade was executed by Eben Tessari on 1 September 2024, trading 6,463 units of KNSA stock currently worth 157,309$.
What does Kiniksa Pharmaceuticals International Plc's logo look like?
Complete history of Eben Tessari stock trades at Kiniksa Pharmaceuticals International Plc
Kiniksa Pharmaceuticals International Plc executives and stock owners
Kiniksa Pharmaceuticals International Plc executives and other stock owners filed with the SEC include:
-
Sanjiv Patel,
Chairman of the Board, Chief Executive Officer -
John Paolini,
Senior Vice President and Chief Medical Officer -
Qasim Rizvi,
Senior Vice President - Operations, Chief Commercial Officer -
Sanj K. Patel,
CEO & Chairman -
Richard Levy,
Independent Director -
Felix Baker,
Lead Independent Director -
Thomas Malley,
Independent Director -
Barry Quart,
Independent Director -
Stephen Biggar,
Independent Director -
Tracey McCain,
Independent Director -
Kimberly Popovits,
Independent Director -
G. Bradley Cole,
Director -
Thomas Beetham,
Executive Vice President, Chief Legal Officer and Corporate Development, and Secretary -
Michael Megna,
Principal Financial Officer, Chief Accounting Officer -
Dr. John F. Paolini,
Sr. VP & Chief Medical Officer -
Mei Jang,
VP of Technical Operations -
Michael R. Megna,
Chief Accounting Officer & VP of Fin. -
Christine Maurer,
Sr. VP of Program Management -
Carsten Boess,
Exec. VP of Corp. Affairs -
Rasmus Holm-Jorgensen,
Sr. VP, Chief Strategy & Portfolio Officer -
Melissa Manno,
Chief HR Officer -
Madelyn Zeylikman,
Gen. Counsel -
Chad Morin,
VP & Chief Compliance Officer -
Mark Ragosa C.F.A.,
Sr. VP & CFO -
Bros. Advisors Lp667, L.P.B...,
-
Asset Management, Lp Chen B...,
-
Stephen F. Mahoney,
President & COO -
James E Deerfield Mgmt L.P....,
-
Carsten Boess,
10% owner -
Chris Heberlig,
EVP & CFO -
Sanj K Patel,
CHAIRMAN & CEO -
Ross Moat,
CHIEF COMMERCIAL OFFICER -
Mark Ragosa,
CHIEF FINANCIAL OFFICER -
Eben Tessari,
CHIEF OPERATING OFFICER -
Arian Pano,
Chief Clinical Dev. Officer